Evidence map›Paper›PMID 41546616›Full record

ArticleJACC. CardioOncology2025

Pretreatment Circulating Vascular Biomarkers Predict Cancer Therapy-Related Cardiac Dysfunction During HER2

Dakota Gustafson, Priya Mistry, Crizza Ching, Inbar Nardi-Agmon, Christopher Yu, Chun-Po Steve Fan, Christian Houbois, Eitan Amir, Thomas Marwick, Husam Abdel-Qadir and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dakota GustafsonToronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Priya MistryToronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Crizza ChingToronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Inbar Nardi-AgmonPeter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Christopher YuPeter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Chun-Po Steve FanTed Rogers Computational Program, Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
Christian HouboisJoint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Eitan AmirPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Thomas MarwickBaker Heart and Diabetes Institute, Melbourne, Australia.
Husam Abdel-QadirPeter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Women's College Hospital, Toronto, Ontario, Canada.
Chris McIntoshToronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada; Department of Computer Science, University of Toronto, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Vector Institute, University of Toronto, Toronto, Ontario, Canada.
Paaladinesh ThavendiranathanPeter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Joint Department of Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada; Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, Department of Medicine, Division of Cardiology, Toronto, Ontario, Canada. Electronic address: dinesh.thavendiranathan@uhn.ca.
Jason E FishToronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada. Electronic address: jason.fish@utoronto.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBlood biomarkers to predict cancer therapy-related cardiac dysfunction (CTRCD) risk remain limited.

objectivesThe aim of this study was to identify circulating biomarkers associated with CTRCD risk in HER2

methodsIn the discovery cohort, women with early-stage HER2

resultsAmong 136 women, 37 (27.2%) developed CMR-defined CTRCD within 15 months. The endothelial activation markers angiopoietin-2, endothelin-1, and endoglin were elevated before and during treatment, while sE-selectin was elevated during treatment in patients who developed CTRCD. Inflammatory biomarkers (myeloperoxidase, interferon-gamma-induced protein-10, and interferon-α) were significantly higher before treatment in patients who developed CTRCD. No differences were observed in cardiac injury biomarkers (troponin I, B-type natriuretic peptide, and growth differentiation factor-15). Pretreatment plasma microRNAs revealed distinct CTRCD-associated signatures. Integrating pretreatment clinical variables, CMR parameters, and biomarkers into a single random forest model, angiopoietin-2, myeloperoxidase, and endoglin were identified as the strongest predictors of CTRCD, findings that were subsequently validated in a cohort of 38 HER2

conclusionsPretreatment endothelial-centric and inflammatory biomarkers outperformed both clinical and CMR measures in predicting CTRCD during chemotherapy.

Indexed as

angiopoeitin-2, biomarkersbreast cancercancer therapy–related cardiac dysfunctioncardio-oncologyendotheliuminflammationmachine learningmicroRNAmyeloperoxidasevascular

Identifiers

PMID41546616
PMCPMC12805402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.